HAEMATO AG
DGAP-News: HAEMATO AG / Key word(s): Quarterly / Interim Statement/Quarter Results HAEMATO AG - IFRS Results Q1 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.8 million (previous year: EUR 68.0 million) and an operating result (EBIT) of EUR 4.0 million in the first quarter of 2018. Sales increased by 2.8% compared to the same period of the previous year. The Executive Board is optimistic that it will achieve the targets set for the 2018 financial year.
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of business activities is on the growth markets of high-priced special pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.
HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the HAEMATO AG share: Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
18.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | HAEMATO AG |
| Lilienthalstraße 5c | |
| 12529 Schönefeld | |
| Germany | |
| Phone: | +49 (0)30 897 30 86 70 |
| Fax: | +49 (0)30 897 30 86 79 |
| E-mail: | ir@haemato.de |
| Internet: | www.haemato.de |
| ISIN: | DE0006190705 |
| WKN: | 619070 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |
687669 18.05.2018
